AAVs are widely used as viral vectors in human gene therapy implementing recombinant DNA technology. Accurate measurement of AAV concentration in complex biological matrices is essential for safe clinical application and effective manufacturing of AAV gene therapies.
Revvity has developed and manufactured a line of immunoassays that detect and quantify AAV capsid with AlphaLISA® technology. These assays can detect AAV1, AAV2, AAV3B, AAV5, AAV6, AAV8, and AAV9 serotypes, and measure AAV particles present in cell culture media, lysis buffer, and cell lysate.
Download Application Note